Lisa M Jacola1, Kim Edelstein2, Wei Liu3, Ching-Hon Pui4, Robert Hayashi5, Nina S Kadan-Lottick6, Deokumar Srivastava3, Tara Henderson7, Wendy Leisenring8, Leslie L Robison9, Gregory T Armstrong9, Kevin R Krull10. 1. Department of Psychology, St Jude Children's Research Hospital, Memphis TN, USA. Electronic address: lisa.jacola@stjude.org. 2. Pencer Brain Tumor Centre, Princess Margaret Cancer Center, Toronto, ON, Canada. 3. Department of Biostatistics, St Jude Children's Research Hospital, Memphis TN, USA. 4. Department of Oncology, St Jude Children's Research Hospital, Memphis TN, USA. 5. Department of Oncology, Washington University at St Louis, St Louis, MO, USA. 6. Yale Section of Pediatric Hematology-Oncology and Yale Cancer Center, New Haven, CT, USA. 7. Department of Oncology, University of Chicago, Chicago, IL, USA. 8. Clinical Research and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 9. Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis TN, USA. 10. Department of Psychology, St Jude Children's Research Hospital, Memphis TN, USA; Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis TN, USA.
Abstract
BACKGROUND: Survivors of childhood acute lymphoblastic leukaemia (ALL) are at risk for neurocognitive deficits that affect development in adolescence and young adulthood, and influence educational attainment and future independence. We examined a large and diverse cohort of survivors to identify risk predictors and modifiers of these outcomes. METHODS: In this cohort study, cognitive and behaviour symptoms were assessed via a standardised parent questionnaire for 1560 adolescent survivors of ALL diagnosed between 1970 and 1999. Clinically significant symptoms (≥90th percentile) and learning problems were compared between survivors and a sibling cohort. Multivariable regression models were used to examine associations with demographic and treatment characteristics. Models were adjusted for inverse probability of sampling weights to reflect undersampling of ALL survivors in the expansion cohort. In a subset of survivors with longitudinal data (n=925), we examined associations between adolescent symptoms or problems and adult educational attainment. FINDINGS: Compared with siblings, survivors treated with chemotherapy only were more likely to demonstrate headstrong behaviour (155 [19%] of 752 survivors vs 88 [14%] of 610 siblings, p=0·010), inattention-hyperactivity (15 [19%] vs 86 [14%], p<0·0001), social withdrawal (142 [18%] vs 75 [12%], p=0·002), and had higher rates of learning problems (191 [28%] vs 76 [14%], p<0·0001). In multivariable models among survivors, increased cumulative dose of intravenous methotrexate (ie, >4·3 g/m2) conferred increased risk of inattention-hyperactivity (relative risk [RR] 1·53, 95% CI 1·13-2·08). Adolescent survivors with cognitive or behaviour problems and those with learning problems were less likely to graduate from college as young adults than adolescent survivors without cognitive or behaviour problems. INTERPRETATION: Although modern therapy for childhood ALL has eliminated the use of cranial radiation therapy, adolescent survivors treated with chemotherapy only remain at increased risk for cognitive, behaviour, and academic problems that adversely affect adult education outcomes. FUNDING: National Cancer Institute, American Lebanese-Syrian Associated Charities.
BACKGROUND: Survivors of childhood acute lymphoblastic leukaemia (ALL) are at risk for neurocognitive deficits that affect development in adolescence and young adulthood, and influence educational attainment and future independence. We examined a large and diverse cohort of survivors to identify risk predictors and modifiers of these outcomes. METHODS: In this cohort study, cognitive and behaviour symptoms were assessed via a standardised parent questionnaire for 1560 adolescent survivors of ALL diagnosed between 1970 and 1999. Clinically significant symptoms (≥90th percentile) and learning problems were compared between survivors and a sibling cohort. Multivariable regression models were used to examine associations with demographic and treatment characteristics. Models were adjusted for inverse probability of sampling weights to reflect undersampling of ALL survivors in the expansion cohort. In a subset of survivors with longitudinal data (n=925), we examined associations between adolescent symptoms or problems and adult educational attainment. FINDINGS: Compared with siblings, survivors treated with chemotherapy only were more likely to demonstrate headstrong behaviour (155 [19%] of 752 survivors vs 88 [14%] of 610 siblings, p=0·010), inattention-hyperactivity (15 [19%] vs 86 [14%], p<0·0001), social withdrawal (142 [18%] vs 75 [12%], p=0·002), and had higher rates of learning problems (191 [28%] vs 76 [14%], p<0·0001). In multivariable models among survivors, increased cumulative dose of intravenous methotrexate (ie, >4·3 g/m2) conferred increased risk of inattention-hyperactivity (relative risk [RR] 1·53, 95% CI 1·13-2·08). Adolescent survivors with cognitive or behaviour problems and those with learning problems were less likely to graduate from college as young adults than adolescent survivors without cognitive or behaviour problems. INTERPRETATION: Although modern therapy for childhood ALL has eliminated the use of cranial radiation therapy, adolescent survivors treated with chemotherapy only remain at increased risk for cognitive, behaviour, and academic problems that adversely affect adult education outcomes. FUNDING: National Cancer Institute, American Lebanese-Syrian Associated Charities.
Authors: Heather J Fullerton; Kayla Stratton; Sabine Mueller; Wendy W Leisenring; Greg T Armstrong; Rita E Weathers; Marilyn Stovall; Charles A Sklar; Robert E Goldsby; Les L Robison; Kevin R Krull Journal: Neurology Date: 2015-08-26 Impact factor: 9.910
Authors: Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman Journal: Pediatr Blood Cancer Date: 2005-09 Impact factor: 3.167
Authors: Kevin R Krull; Tara M Brinkman; Chenghong Li; Gregory T Armstrong; Kirsten K Ness; Deo Kumar Srivastava; James G Gurney; Cara Kimberg; Matthew J Krasin; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-04 Impact factor: 44.544
Authors: Sabine Mueller; Heather J Fullerton; Kayla Stratton; Wendy Leisenring; Rita E Weathers; Marilyn Stovall; Gregory T Armstrong; Robert E Goldsby; Roger J Packer; Charles A Sklar; Daniel C Bowers; Leslie L Robison; Kevin R Krull Journal: Int J Radiat Oncol Biol Phys Date: 2013-05-14 Impact factor: 7.038
Authors: Nicholas S Phillips; Yin Ting Cheung; John O Glass; Matthew A Scoggins; Wei Liu; Robert J Ogg; Daniel A Mulrooney; Ching-Hon Pui; Leslie L Robison; Wilburn E Reddick; Melissa M Hudson; Kevin R Krull Journal: Pediatr Blood Cancer Date: 2019-08-12 Impact factor: 3.167
Authors: Wei Liu; Yin Ting Cheung; Tara M Brinkman; Pia Banerjee; Deokumar Srivastava; Vikki G Nolan; Hongmei Zhang; James G Gurney; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Psychooncology Date: 2018-03-30 Impact factor: 3.894
Authors: Stephanie B Dixon; Yan Chen; Yutaka Yasui; Ching-Hon Pui; Stephen P Hunger; Lewis B Silverman; Kirsten K Ness; Daniel M Green; Rebecca M Howell; Wendy M Leisenring; Nina S Kadan-Lottick; Kevin R Krull; Kevin C Oeffinger; Joseph P Neglia; Ann C Mertens; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Paul C Nathan Journal: J Clin Oncol Date: 2020-07-24 Impact factor: 44.544
Authors: Kevin R Krull; Kristina K Hardy; Lisa S Kahalley; Ilse Schuitema; Shelli R Kesler Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: Lisa M Jacola; Julie Baran; Robert B Noll; Victoria W Willard; Kristina K Hardy; Leanne Embry; Stephanie E Hullmann; Eric C Larsen; Naomi Winick; John A Kairalla Journal: Pediatr Blood Cancer Date: 2021-01-31 Impact factor: 3.167
Authors: AnnaLynn M Williams; Edwin van Wijngaarden; Christopher L Seplaki; Charles E Heckler; Miriam T Weber; Paul M Barr; Clive S Zent; Michelle C Janelsins Journal: Leuk Lymphoma Date: 2020-03-09
Authors: Marita Partanen; Sean Phipps; Kathryn Russell; Doralina L Anghelescu; Joshua Wolf; Heather M Conklin; Kevin R Krull; Hiroto Inaba; Ching-Hon Pui; Lisa M Jacola Journal: J Pediatr Psychol Date: 2021-02-19